EPO Scathed But Survives ODAC Challenge; Cmte. Calls For Additional Trials
Executive Summary
Sponsors of erythropoiesis-stimulating agents should conduct additional safety studies to support continued marketing in the oncology setting, FDA's Oncologic Drugs Advisory Committee unanimously recommends
You may also be interested in...
From Avastin To Zevalin: ODAC’s Most Memorable Moments
The current and former leaders of FDA’s Oncologic Drugs Advisory Committee recount their most memorable moments of service on the panel.
Amgen Wins Supreme Court Review Of EPO Securities Fraud Class Certification
The court will decide whether a party seeking class certification must show that a company’s alleged misrepresentations are material; investors claim Amgen misrepresented the safety of Aranesp and Epogen prior to a May 2004 FDA advisory committee meeting.
FDA Panel Votes To Limit ESA Cancer Use To Metastatic Patients
Following the recommendations of its Oncologic Drugs Advisory Committee, FDA's next step in ensuring the safe use of erythropoiesis-stimulating agents will be to determine how best to narrow the approved indication for anemia treatment in the cancer setting